{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T11:00:14Z","timestamp":1771844414076,"version":"3.50.1"},"reference-count":30,"publisher":"Hindawi Limited","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1302,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1111\/j.1742-1241.2011.02806.x","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T19:46:22Z","timestamp":1328643982000},"page":"399-408","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis"],"prefix":"10.1155","volume":"66","author":[{"given":"T.","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.-Z.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-M.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z.-M.","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.-Z.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.-G.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2012,2,7]]},"reference":[{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1359\/jbmr.1997.12.1.16","article-title":"Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation","volume":"12","author":"Melton","year":"1997","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00198-006-0179-x","article-title":"Compliance with drug therapy for postmenopausal osteoporosis","volume":"17","author":"Weycker","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB3|cit3","first-page":"115","article-title":"[Pharmacological actions and pharmacokinetics of bisphosphonates]","volume":"13","author":"Takeyama","year":"2003","journal-title":"Clin Calcium"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s00198-004-1725-z","article-title":"Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women","volume":"16","author":"Papapoulos","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1055\/s-2006-946559","article-title":"[Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment]","volume":"131","author":"Bartl","year":"2006","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1083\/jcb.145.3.527","article-title":"The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts","volume":"145","author":"Burgess","year":"1999","journal-title":"J Cell Biol"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1345\/aph.1M102","article-title":"Denosumab in osteoporosis and oncology","volume":"43","author":"Burkiewicz","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB10|cit10","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2011.03.005","article-title":"Clinical efficacy and safety of denosumab in postmenopausal women with low bone mineral density and osteoporosis: a meta-analysis","author":"von Keyserlingk","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1084\/jem.186.12.2075","article-title":"TRANCE [tumor necrosis factor (TNF)-related activation-induced cytokine], a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor","volume":"186","author":"Wong","year":"1997","journal-title":"J Exp Med"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1056\/NEJMc060819","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"Schwartzman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB14|cit14","doi-asserted-by":"crossref","DOI":"10.1002\/9780470712184","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2008"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"BMJ"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.090716","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy","volume":"25","author":"Kendler","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/jbmr.81","article-title":"Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate","volume":"25","author":"Seeman","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jocd.2008.04.001","article-title":"Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate","volume":"11","author":"Beck","year":"2008","journal-title":"J Clin Densitom"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1359\/jbmr.091003","article-title":"Dependence of bone yield (volume of bone formed per unit of cement surface area) on resorption cavity size during osteonal remodeling in human rib: implications for osteoblast function and the pathogenesis of age-related bone loss","volume":"25","author":"Qiu","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality--the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.bone.2010.11.020","article-title":"Denosumab and bisphosphonates: different mechanisms of action and effects","volume":"48","author":"Baron","year":"2011","journal-title":"Bone"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3945\/jn.110.132126","article-title":"Cortical and trabecular bone, bone mineral density, and resistance to ex vivo fracture are not altered in response to life-long vitamin A supplementation in aging rats","volume":"141","author":"Wray","year":"2011","journal-title":"J Nutr"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s001980200025","article-title":"Trabecular and cortical bone in the assessment of vertebral fracture risk","volume":"13","author":"Russo","year":"2002","journal-title":"Osteoporos Int"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/978-0-387-72009-8_18","article-title":"RANKL inhibition: from mice to men (and women)","volume":"602","author":"Stolina","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"10.1111\/j.1742-1241.2011.02806.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2011.02806.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2011.02806.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:05:57Z","timestamp":1643349957000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2011.02806.x"}},"subtitle":["Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women"],"short-title":[],"issued":{"date-parts":[[2012,2,7]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02806.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2,7]]}}}